Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00608881 · ClinicalTrials.gov registry record · Phase 3
Coenzyme Q10 in Huntington's Disease (HD)
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Terminated
- Registry status
- Phase 3
- Development phase
- 609
- Enrollment target
NCT00608881: Clinical Trial Phase 3 study, sponsored by Massachusetts General Hospital.
NCT00608881 is a Phase 3 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 609 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00608881, a Phase 3 study, was terminated before completion, sponsored by Massachusetts General Hospital.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 609 participants
- Enrollment target
Study Summary
The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its effects on people with Huntington's disease.
Interventions
- OTHER placebo
- DRUG coenzyme Q10
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2008-03 |
| Est. Completion | 2015-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00608881
The ClinicalTrials.gov registry entry for NCT00608881 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT00608881 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00608881 about?
NCT00608881 is a clinical study titled "Coenzyme Q10 in Huntington's Disease (HD)". The goals of this trial are to determine if coenzyme Q10 is effective in slowing the worsening symptoms of Huntington's disease and to learn about the safety and acceptability of long-term coenzyme Q10 use by determining its effects on people with Huntington's disease.
What is the current status of trial NCT00608881?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 609 participants. The study started on 2008-03. Estimated completion is 2015-05.
What interventions are being tested in trial NCT00608881?
The interventions under investigation include: placebo (OTHER), coenzyme Q10 (DRUG).
Who is sponsoring clinical trial NCT00608881?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.